Paysign's Pharma segment now drives over half of revenue, growing 110% with higher margins and a larger TAM. Read why PAYS stock is a Strong Buy.
PaySign Inc (PAYS) posted record Q3 2026 revenue of $30.8 million and raised full-year guidance, even as one plasma customer's 113-center move clouds fourth-quarter growth.
Fintech stock Paysign scores a new high Friday with a year-to-date gain of 203%. Paysign provides finance tools for several industries.
Tipranks Press Release.
Tipranks Press Release.
Paysign grew Q2 revenue 48.1% YoY to $28.3 million, raised 2026 guidance twice, and got plasma growing 21.4% after a flat 2025. Learn more about PAYS stock here.
Paysign (NASDAQ:PAYS) operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation. Baker described the company as both a payments and life sciences business
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
This is the newest page. Registered accounts read further back.